ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1997

Health Care Utilization In Gout Patients: A Prospective Multicenter Cohort Study

Jasvinder A. Singh1,2, Aseem Bharat3, Puja Khanna4, Cleopatra Aquino-Beaton5, Jay E. Persselin6, Erin Duffy7, David Elashoff8 and Dinesh Khanna9, 1Rheumatology, Birmingham VA, Birmingham, AL, 2Department of Medicine, University of Alabama, Tuscaloosa, AL, 3Medicine/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 4Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, 5Rheumatology, VA Greater Los Angeles Healthcare System, Los Angeles, CA, 6Medicine W-111J Div of Rheum, VA Greater Los Angeles Healthcare System, Los Angeles, CA, 7Medicine, University of California Los Angeles, Los Angeles, CA, 8Medicine- Statistic Core, UCLA Department of Medicine Statistics Core, Los Angeles, CA, 9University of Michigan, Ann Arbor, MI

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Gout and utilization review

  • Tweet
  • Email
  • Print
Session Information

Title: Metabolic and Crystal Arthropathies II

Session Type: Abstract Submissions (ACR)

Background/Purpose: Because of the chronic nature of the disease, gout is associated with more co-morbidities, poor health-related quality of life (HRQoL) and more healthcare utilization (HCU). Therefore, the cost of care associated with gout management is rising. There is lack of evidence that describes the predictions of health care utilization in patients with gout. The objective of this study is to assess health care utilization and its predictors in patients with gout.

Methods: We conducted a prospective cohort study of 186 veterans with gout (predominantly male) recruited at Veterans Affairs (VA) rheumatology and primary care clinics at the West Los Angeles, CA and Birmingham, AL facilities. We assessed overall health care utilization with the patient self-reported University of California at San Diego (UCSD) Health Care Utilization Questionnaire and gout-specific health care utilization on the Gout Assessment Questionnaire (GAQ) every 3 months for a 9-month period. We collected data including patient demographics, education level, comorbidity, serum urate (in mg/dl) and patient and physician rating of the severity of gout on a 0-10 scale, HRQOL assessment with SF-36, and the Gout Impact Scales (GIS) of the GAQ and functional ability assessed with Health Assessment Questionnaire-Disability Index (HAQ-DI), were assessed. Comparisons were made using the student’s t test or the chi-square, Wilcoxon rank sum test or Fisher exact test, as appropriate. Zero-inflated Poisson regression was used to assess potential predictors of gout-related HCU.

Results:  The cohort mean age was 64.6 years, 98% were men, 13% Hispanic or Latino, 6% did not graduate high school, the mean serum urate was 8.3, mean physician gout severity assessment was 3.1 and mean patient gout severity assessment was 5.7. Mean Deyo-Charlson score was 3.1.

Overall health care Utilization: There were a mean of 3.9 visits to the health care provider in the past 3 months and 1.7 telephone calls to the provider or medical staff (Table).  17% had 1 or more inpatient visits in the past 3 months, 41% had 1 or more ER/urgent care/triage center visits and 16% with any outpatient procedure or surgery (Table).

Gout-specific health care utilization: During the past year, patients had a mean of 1.5 visits to rheumatologist, 2 visits to primary care doctor (Table).  7% had 1 or more inpatient visits in the past year related to gout, 26% had 1 or more ER visits related to gout and 33% with any urgent care/walk-in visit related to gout (Table 2).

Conclusion: This cohort study is the first prospective cohort study to examine health care utilization in patients with gout. We have described patterns of health care utilization by patients with gout in the U.S. Future studies need to examine whether modifiable predictors of utilization can be targeted to reduce the overall and gout-related utilization in patients.

 

Healthcare Utilization

 

Patients with at least one visit/call

Number of visits/calls

 

N

%

Mean (SD)

 

Total

N=186

BHAM

N=74

LA

N=112

Total

N=186

BHAM

N=74

LA

N=112

Total

N=186

BHAM

N=74

LA

N=112

 Overall HCU, prior 3 months:

 

 

 

 

 

 

 

 

 

 

 

 

Number of visits to MD, DO, or NP

163

 63

100

 92 %

88 %

95 %

3.9

(4.3)

2.8

(2.5)

4.6

(5.1)

Number of phone calls to MD or medical staff

85

 32

53

 48 %

44 %

 50 %

1.7

(3.1)

1.4

(2.3)

1.9

(3.5)

Number of times to a triage, urgent care center, or emergency room

74

 31

43

 41 %

43 %

 40 %

0.6

(0.9)

0.6

(0.9)

0.6

(1.0)

Number of home visits by healthcare provider

16

 6

10

 9 %

8 %

 9 %

0.6

(2.4)

0.5

(1.9)

0.6

(2.8)

Number of days as inpatient

 31

 11

20

 17 %

15 %

 19 %

1.8

(9.6)

0.6

(1.6)

2.7

(12.3)

Number of outpatient surgeries or procedures

27

 15

 12

 16 %

23 %

 12 %

0.3

(0.9)

0.4

(1.1)

0.2

(0.7)

Gout related HCU, prior year:

 

 

 

 

 

 

 

 

 

 

 

 

Rheumatologist

97

20

77

53 %

28 %

70 %

1.5

(2.0)

1.2

(2.4)

1.7

(2.4)

Primary Care Doctor

128

57

71

71 %

79 %

66 %

2.0

(1.9)

2.0

(1.5)

2.0

(1.5)

Nurse Practitioner or Physician’s Assistant

53

8

45

31 %

12 %

43 %

0.8

(1.6)

0.2

(0.7)

1.2

(0.7)

Walk-in or Urgent Care Clinic

57

21

36

33 %

31 %

34 %

0.7

(1.5)

0.6

(0.9)

0.8

(0.9)

Emergency Room at a hospital

45

22

23

26 %

31 %

22 %

0.4

(0.8)

0.4

(0.8)

0.4

(0.8)

Hospital Over-night Stay

17

5

12

10 %

7 %

11 %

0.7

(7.5)

0.1

(0.4)

1.1

(0.4)


Disclosure:

J. A. Singh,

Takeda, Savient,

2,

Savient, Takeda, Ardea, Regeneron, Allergan,

5,

URL pharmaceuicals Novartis,

5;

A. Bharat,
None;

P. Khanna,
None;

C. Aquino-Beaton,
None;

J. E. Persselin,
None;

E. Duffy,
None;

D. Elashoff,
None;

D. Khanna,

savient,

2,

Savient, Takeda, and AZ,

5.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/health-care-utilization-in-gout-patients-a-prospective-multicenter-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology